Intended Use
Assesses genetic risk of abnormal drug metabolism for CYP2C19 substrates. May aid in drug selection and dose planning for drugs metabolized by CYP2C19.
Specimen Required
Lavender (EDTA), Pink (K2EDTA), FFPE
Patient Preparation
- Sample Collection: 2 Tubes / EDTA Blood / 2 mL per tube or FFPE
- Specimen Preparation: Do not freeze. Transport 3 mL whole blood. (Min: 1 mL)
- Storage/Transport Temperature: Refrigerated
- Unacceptable Conditions
- Plasma or serum.
- Heparinized specimens.
- Frozen specimens in glass collection tubes.
- Remarks: –
- Stability: Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month.
Methodology
The procedure is based on PCR amplification and hybridization of amplification products to a test strip containing allele-specific oligonucleotide probes. The assay covers 8 polymorphic loci.
Sample Received to Report Turnaround Time (TAT)
Twice in a week (Scheduled test)
Reference Interval
–
Interpretive Data
Refer to report
Resources
- Additional Technical Information
- Test Request Form
Sample Reports
- Enhanced Report
- See report